About the Company
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for inflammatory and immune-related diseases with clear unmet medical needs. The company's two lead product candidates, EB05 and EB01, are in later stage clinical studies. EB05 is a monoclonal antibody therapy that it's developing as a treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 patients. ARDS is a life-threatening form of respiratory failure, and the leading cause of death among COVID-19 patients. Edesa is also developing an sPLA2 inhibitor, designated as EB01, as a topical treatment for chronic allergic contact dermatitis (ACD), a common, potentially debilitating condition and occupational illness. EB01 employs a novel, non-steroidal mechanism of action and in two clinical studies has demonstrated statistically significant improvement of multiple symptoms in ACD patients. The company is based in Markham, Ontario, Canada, with a U.S. subsidiary located in Southern California.
Employees
12
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $EDSA News
Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Conference
TORONTO, ON / ACCESSWIRE / / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on ...
3 Biotech Stocks That Could Be Multibaggers in the Making: March Edition
Last year was a tough one for biotech stocks. The Securities and Exchange Commission reported 41 bankruptcies following the ...
2 Top Biotech Buyout Candidates
ETFs like XBI and the iShares Biotech ETF (IBB) are the best instruments for risk-averse investors to take advantage of renewed interest in the sector while avoiding risky binary events like FDA ...
Biotech Stock News Bite - Elicio Therapeutics, Inc. (Nasdaq: ELTX) Rises on Funding News
Investorideas.com ( Biotech Stock News Bites - Elicio Therapeutics, Inc. (Nasdaq: ELTX), a clinical-stage biotechnology ...
Loading the latest forecasts...